KemPharm (NASDAQ:KMPH) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.46), Fidelity Earnings reports.
Shares of NASDAQ KMPH opened at $1.20 on Thursday. KemPharm has a fifty-two week low of $1.15 and a fifty-two week high of $7.15. The stock has a market cap of $32.54 million, a PE ratio of -0.48 and a beta of 1.63.
An institutional investor recently raised its position in KemPharm stock. Geode Capital Management LLC lifted its holdings in shares of KemPharm Inc (NASDAQ:KMPH) by 136.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 171,047 shares of the specialty pharmaceutical company’s stock after acquiring an additional 98,775 shares during the period. Geode Capital Management LLC owned 0.65% of KemPharm worth $304,000 at the end of the most recent reporting period. Institutional investors own 34.30% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.